טוען...
2414. Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated With Ceftolozane/Tazobactam Across 253 US Hospitals
BACKGROUND: Treatment of patients with Gram negative infections is increasingly difficult due to rising resistance to commonly used agents. Ceftolozane/tazobactam (C/T) is a potent anti-pseudomonal agent with broad Gram-negative coverage, that is indicated for cUTI and cIAI and currently being studi...
שמור ב:
| הוצא לאור ב: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6253216/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2067 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|